Phase II trial of medroxyprogesterone acetate in advanced ovarian cancer: an EORTC Gynecological Cancer Cooperative Group Study.

Hamerlynck, J V; Maskens, A P; Mangioni, C; van der Burg, M E; Wils, J A; Vermorken, J B; Rotmensz, N

Hamerlynck, J V; Maskens, A P; Mangioni, C; van der Burg, M E; Wils, J A; Vermorken, J B; Rotmensz, N.

Gynecol Oncol ; 22(3): 313-6, 1985 Nov.

Article in En | MEDLINE | ID: mdl-2998957

Subject(s)

Medroxyprogesterone/analogs & derivatives; Ovarian Neoplasms/drug therapy; Adenocarcinoma/drug therapy; Adenocarcinoma, Mucinous/drug therapy; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Carcinoma/drug therapy; Drug Evaluation; Drug Resistance; Endometriosis/drug therapy; Female; Humans; Medroxyprogesterone/administration & dosage; Medroxyprogesterone/adverse effects; Medroxyprogesterone/therapeutic use; Medroxyprogesterone Acetate; Middle Aged

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Medroxyprogesterone Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Gynecol Oncol Year: 1985 Document type: Article Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links